XenoTherapeutics to Start First Human Trial of Xeno-Skin™, a Novel Xenotransplantation Treatment for Severe Burns

December 8, 2018

XenoTherapeutics, a life science company whose mission is to solve the global shortage of organs and tissues for transplants, announced today that the U.S. Food and Drug Administration has cleared the company’s Investigational New Drug application (IND #18914) allowing clinical studies of Xeno-Skin™ to be initiated. Xeno-Skin is a first-of-its-kind xenotransplantation product, designed to provide a safe temporary coverage mechanism for patients with severe burn wounds. The company is inactive preparations to enroll patients for a first-in-human clinical study of Xeno-Skin at Massachusetts General Hospital (MGH) by the end of 2018.

Contact Us

359 Newbury Street, 5th Floor Suite 526

Boston, MA 02115

617-939-7892

info@xenotherapeutics.org

Connect with us
SUBSCRIBE

Federal EIN Number: 81-1016095

© 2020 by XenoTherapeutics Foundation

  • Black Facebook Icon
  • Black Twitter Icon
  • LinkedIn